Keywords: Merck KGaA, cladribine, FDA approval delay

US FDA delays Merck KGaA’s filing on MS drug cladribine

Article | 1 December 2009

In a move that will delay the approval of German drug major Merck KGaA’s multiple sclerosis drug cladribine, the US Food and Drug Administration has issued a “refuse to file” letter on the firm’s New Drug Application for the compound as a therapy for relapsing forms of MS.

M Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in